In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $0.20 in the prior trading day, Carisma Therapeutics Inc (NASDAQ: CARM) closed at $0.18, down -11.15%. In other words, the price has decreased by -$11.15 from its previous closing price. On the day, 0.76 million shares were traded.
Ratios:
Our goal is to gain a better understanding of CARM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.34 and its Current Ratio is at 1.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on December 12, 2024, Downgraded its rating to Neutral and sets its target price to $1 from $10 previously.
On April 11, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on April 11, 2024, with a $6 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37.
Stock Price History:
Over the past 52 weeks, CARM has reached a high of $1.90, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is -18.95%, while the 200-Day Moving Average is calculated to be -70.80%.
Shares Statistics:
A total of 41.79M shares are outstanding, with a floating share count of 21.12M. Insiders hold about 49.46% of the company’s shares, while institutions hold 11.10% stake in the company.
Earnings Estimates
The current rating of Carisma Therapeutics Inc (CARM) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.41 and -$0.41 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.66, with 1.0 analysts recommending between -$0.66 and -$0.66.
Revenue Estimates
1 analysts predict $3.75M in revenue for the current quarter. It ranges from a high estimate of $3.75M to a low estimate of $3.75M. As of the current estimate, Carisma Therapeutics Inc’s year-ago sales were $9.2MFor the next quarter, 1 analysts are estimating revenue of $3.75M. There is a high estimate of $3.75M for the next quarter, whereas the lowest estimate is $3.75M.
A total of 1 analysts have provided revenue estimates for CARM’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $15M, resulting in an average revenue estimate of $15M. In the same quarter a year ago, actual revenue was $19.63M
